期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 130, 期 5, 页码 2237-2251出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI133194
关键词
-
资金
- Wellcome Trust [106241/Z/14/Z, FC001501]
- Oxford Branch of the Ludwig Institute for Cancer Research
- Paradifference Foundation
- Francis Crick Institute
- Cancer Research UK [FC001501]
- UK Medical Research Council [FC001501]
- FAPESP fellowship [2018/20083-1]
- Boehringer Ingelheim Fonds
- Wellcome Trust [106241/Z/14/Z] Funding Source: Wellcome Trust
Hypoxia-inducible factor (HIF) is strikingly upregulated in many types of cancer, and there is great interest in applying inhibitors of HIF as anticancer therapeutics. The most advanced of these are small molecules that target the HIF-2 isoform through binding the PAS-B domain of HIF-2 alpha. These molecules are undergoing clinical trials with promising results in renal and other cancers where HIF-2 is considered to be driving growth. Nevertheless, a central question remains as to whether such inhibitors affect physiological responses to hypoxia at relevant doses. Here, we show that pharmacological HIF-2 alpha inhibition with PT2385, at doses similar to those reported to inhibit tumor growth, rapidly impaired ventilatory responses to hypoxia, abrogating both ventilatory acclimatization and carotid body cell proliferative responses to sustained hypoxia. Mice carrying a HIF-2 alpha PAS-B S305M mutation that disrupts PT2385 binding, but not dimerization with HIF-1 beta, did not respond to PT2385, indicating that these effects are on-target. Furthermore, the finding of a hypomorphic ventilatory phenotype in untreated HIF-2 alpha S305M mutant mice suggests a function for the HIF-2 alpha PAS-B domain beyond heterodimerization with HIF-1 beta. Although PT2385 was well tolerated, the findings indicate the need for caution in patients who are dependent on hypoxic ventilatory drive.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据